Recursion harnesses AI for large-scale drug discovery, while Summit's betting on a single oncology candidate. How do their ...

How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...

The most capable one didn't make the cut.

Everyone is racing to point powerful AI models at drug discovery. A growing camp argues the real prize is the layer beneath the models — the connected biological knowledge they reason over — and that ...

Abstract: We introduce isQ, a new software stack for quantum programming in an imperative programming language, also named isQ. The aim of isQ is to make programmers write quantum programs as ...

Multiple milestones achieved or on track across wholly owned and partnered programs REC-1245 (RBM39 degrader): Early clinical data in solid tumors demonstrate a well-tolerated safety profile and ...

One of the key challenges of current multi-agent AI systems is that they communicate by generating and sharing text sequences, which introduces latency, drives up token costs, and makes it difficult ...

Brand-new startups are continuing to raise massive rounds to work on new niches of AI. Recursive, a stealth-mode AI lab, has emerged from the shadows with one an audacious pitch: build an AI that ...

Thanks for attending the 2026 Bank of America Healthcare Conference. My name is Alec Stranahan. I cover Recursion and SMid Biotech at Bank of America. And I'm pleased to be joined today by Ben Taylor, ...

Detailed price information for Recursion Pharmaceuticals Inc Cl A (RXRX-Q) from The Globe and Mail including charting and trades.

Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) is one of the best AI stocks under $50 to buy right now. On May 6, Recursion reported significant progress across its AI-driven clinical pipeline for Q1 ...